Blood:止血通过释放和激活VEGFC刺激淋巴管生成

2019-10-03 MedSci MedSci原创

组织损伤后止血,然后伤口愈合是一个复杂的过程,在这个过程中,受损的细胞物质被移除,组织被修复。血管生成反应是伤口愈合的一个重要方面,包括新淋巴管的生成,免疫细胞、蛋白质和液体均通过淋巴管运输出伤口区域。止血反应可能与伤口愈合反应相联系的概念由来已久,但在体内证明这种联系并确定这两个过程相联系的特定分子机制是困难的。在本研究中,研究人员发现凝血酶和纤溶酶(止血和伤口愈合过程中产生的丝氨酸蛋白酶)可以

组织损伤后止血,然后伤口愈合是一个复杂的过程,在这个过程中,受损的细胞物质被移除,组织被修复。血管生成反应是伤口愈合的一个重要方面,包括新淋巴管的生成,免疫细胞、蛋白质和液体均通过淋巴管运输出伤口区域。

止血反应可能与伤口愈合反应相联系的概念由来已久,但在体内证明这种联系并确定这两个过程相联系的特定分子机制是困难的。在本研究中,研究人员发现凝血酶和纤溶酶(止血和伤口愈合过程中产生的丝氨酸蛋白酶)可以裂解淋巴管生成因子VEGFC和VEGFD。在小鼠中,通过一种新的尾部损伤实验来测试血栓形成和淋巴管生成之间的关系,研究人员发现在损伤后,血小板可加速淋巴管的生成。

遗传学研究表明,损伤后血小板增强淋巴管生成依赖于VEGFC的释放,而非VEGFD,这一结果与VEGFC在血小板中的高表达一致。全层皮肤切除术后的淋巴管生成分析显示,与血块形成无明显关系的创伤模型也揭示了VEGFC的重要作用,而非VEGFD。

综上所述,本研究明确了伤口愈合过程中止血与淋巴管生成之间的具体分子和细胞联系,并揭示了胚胎发育过程中起主导作用的淋巴管生成因子VEGFC在成熟动物的淋巴管生成中继续起主导作用。

原始出处:

Lillian Lim, et al.Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC.Blood 2019 :blood.2019001736; doi: https://doi.org/10.1182/blood.2019001736

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937097, encodeId=30d2193e09760, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Apr 09 03:39:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263079, encodeId=26d912630e9a0, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368535, encodeId=5f99136853548, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529377, encodeId=f69615293e7d5, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937097, encodeId=30d2193e09760, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Apr 09 03:39:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263079, encodeId=26d912630e9a0, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368535, encodeId=5f99136853548, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529377, encodeId=f69615293e7d5, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
    2019-10-05 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937097, encodeId=30d2193e09760, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Apr 09 03:39:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263079, encodeId=26d912630e9a0, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368535, encodeId=5f99136853548, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529377, encodeId=f69615293e7d5, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937097, encodeId=30d2193e09760, content=<a href='/topic/show?id=9d8c659e83e' target=_blank style='color:#2F92EE;'>#淋巴管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65978, encryptionId=9d8c659e83e, topicName=淋巴管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Apr 09 03:39:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263079, encodeId=26d912630e9a0, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368535, encodeId=5f99136853548, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529377, encodeId=f69615293e7d5, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Oct 05 13:39:00 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
    2019-10-05 amyloid

相关资讯

静脉抽血后止血的4大误区,你知道吗?

血液是身体健康检查中非常重要的一个指标,抽血化验也是临床护理最常见的项目。不过,总有患者抽血完后胳膊出现青肿,有人的胳膊还会鼓起一个大包。甚至有些患者觉得你的技术很渣。这是神马原因?你知道吗?对,就是没有正确止血!

当肺栓塞合并出血:要不要止血?该不该抗凝、溶栓?

肺栓塞的治疗方法以内科治疗为主,其中抗凝与溶栓治疗是主要手段。常用的抗凝药物包括普通肝素、低分子肝素、华法林、非维生素K拮抗剂类口服抗凝药(利伐沙班、达比加群等),常用溶栓药物包括重组组织型纤溶酶原激活剂(rt-PA)、尿激酶、链激酶等。以上这些药物通过抗凝、促进纤维蛋白溶解起到治疗肺栓塞的作用,而其最大不良反应即是各种出血,包括伴有严重后果的大出血、以及临床相关的非大出血等。

Blood:功能异常的FIX可干扰正常的FIX发挥止血作用

IX因子(FIX)可与内皮细胞下基底膜的胶原IV (Col4)结合。在B型血友病中,FIX-Col4的结合可减少输注的FIX的血浆回收率,在止血过程中具有重要意义。在交联反应阴性(cross-reactive material negative, CRM-)的B型血友病小鼠模型中评估输注的BeneFix(FIXWT)的回收情况的研究表明Col4结合FIX的适合浓度为~405 nM(95% CI 3

NEJM:Andexanet用于Xa因子抑制剂后出血的止血效果研究

研究认为,对于因Xa因子抑制剂出现大出血的患者,接受Andexanet治疗可显著降低抗Xa因子活性, 82%的患者具有良好的止血效果

ATVB:急性缺血性卒中止血生物标志物的意义

由此可见,基于目前的文献没有明确的建议可以提供止血生物标志物是急性缺血性卒中后临床结局的预测因子。然而,一些生物标志物显示出有前景的结果,并且需要大样本研究来进一步验证。

J Endod:氯化铝和电灼法在尖周外科手术中的比较:一项随机对照试验

这篇研究的目的是为了比较和评估2种在尖周外科手术时应用的止血方法以及它们基于患者和牙齿变量的相互关系。